Logo image
Control of the post-infarct immune microenvironment through biotherapeutic and biomaterial-based approaches
Journal article   Open access   Peer reviewed

Control of the post-infarct immune microenvironment through biotherapeutic and biomaterial-based approaches

Shreya S. Soni, Arielle M. D’Elia and Christopher B. Rodell
Drug delivery and translational research
10 Feb 2023
PMID: 36763330
url
https://link.springer.com/content/pdf/10.1007/s13346-023-01290-2.pdfView
Published, Version of Record (VoR) Open
url
https://doi.org/10.1007/s13346-023-01290-2View
Published, Version of Record (VoR) Open

Abstract

Biomaterials Biotherapeutics Heart failure Immune modulation Inflammatory disease Original
Ischemic heart failure (IHF) is a leading cause of morbidity and mortality worldwide, for which heart transplantation remains the only definitive treatment. IHF manifests from myocardial infarction (MI) that initiates tissue remodeling processes, mediated by mechanical changes in the tissue (loss of contractility, softening of the myocardium) that are interdependent with cellular mechanisms (cardiomyocyte death, inflammatory response). The early remodeling phase is characterized by robust inflammation that is necessary for tissue debridement and the initiation of repair processes. While later transition toward an immunoregenerative function is desirable, functional reorientation from an inflammatory to reparatory environment is often lacking, trapping the heart in a chronically inflamed state that perpetuates cardiomyocyte death, ventricular dilatation, excess fibrosis, and progressive IHF. Therapies can redirect the immune microenvironment, including biotherapeutic and biomaterial-based approaches. In this review, we outline these existing approaches, with a particular focus on the immunomodulatory effects of therapeutics (small molecule drugs, biomolecules, and cell or cell-derived products). Cardioprotective strategies, often focusing on immunosuppression, have shown promise in pre-clinical and clinical trials. However, immunoregenerative therapies are emerging that often benefit from exacerbating early inflammation. Biomaterials can be used to enhance these therapies as a result of their intrinsic immunomodulatory properties, parallel mechanisms of action (e.g., mechanical restraint), or by enabling cell or tissue-targeted delivery. We further discuss translatability and the continued progress of technologies and procedures that contribute to the bench-to-bedside development of these critically needed treatments.

Metrics

14 Record Views
5 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Instruments & Instrumentation
Medicine, Research & Experimental
Pharmacology & Pharmacy
Logo image